Prokidney Corp. - Class A (PROK) closed at $1.10 on November 17, 2026, up 5.8% from the previous close, on volume of 1,098,030 shares (30-day average 1,324,319).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Arrowhead Pharmaceuticals (ARWR)
TipRanks (Fri, 13-Nov 4:00 PM ET)
H.C. Wainwright Remains a Buy on ProKidney (PROK)
TipRanks (Fri, 13-Nov 9:45 AM ET)
ProKidney GAAP EPS of -$0.17 misses by $0.03, revenue of $0.17M beats by $0.05M
Seeking Alpha News (Thu, 12-Nov 5:01 PM ET)
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Thu, 12-Nov 4:10 PM ET)
Globe Newswire (Thu, 22-Oct 8:45 AM ET)
Globe Newswire (Thu, 22-Oct 8:00 AM ET)
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Prokidney Corp. - Class A trades on the NASDAQ stock market under the symbol PROK.
As of November 17, 2026, PROK stock price climbed to $1.10 with 1,098,030 million shares trading.
PROK has a beta of 2.20, meaning it tends to be more sensitive to market movements. PROK has a correlation of 0.14 to the broad based SPY ETF.
PROK has a market cap of $229.82 million. This is considered a Small Cap stock.
Last quarter Prokidney Corp. - Class A reported $174,000 in Revenue and -$.17 earnings per share. This beat revenue expectation by $34,320 and missed earnings estimates by -$.03.
In the last 3 years, PROK traded as high as $7.13 and as low as $.46.
The top ETF exchange traded funds that PROK belongs to (by Net Assets): VXF, IWM, VTWO, SCHA, IWO.
PROK has underperformed the market in the last year with a return of -54.4%, while the SPY ETF gained +10.1%. In the last 3 month period, PROK fell short of the market, returning -17.3%, while SPY returned -5.4%. However, in the most recent 2 weeks PROK has outperformed the stock market by returning -1.8%, while SPY returned -2.6%.
PROK support price is $.98 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PROK shares will trade within this expected range on the day.